Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Cytostatic Therapy | Research

Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy

Authors: Min Woo Kim, Hyojung Lee, Suji Lee, Sol Moon, Young Kim, Joon Ye Kim, Seung Il Kim, Jee Ye Kim

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Predicting tumor responses to neoadjuvant chemotherapy (NAC) is critical for evaluating prognosis and designing treatment strategies for patients with breast cancer; however, there are no reliable biomarkers that can effectively assess tumor responses. Therefore, we aimed to evaluate the clinical feasibility of using extracellular vesicles (EVs) to predict tumor response after NAC.

Methods

Drug-resistant triple-negative breast cancer (TNBC) cell lines were successfully established, which developed specific morphologies and rapidly growing features. To detect resistance to chemotherapeutic drugs, EVs were isolated from cultured cells and plasma samples collected post-NAC from 36 patients with breast cancer.

Results

Among the differentially expressed gene profiles between parental and drug-resistant cell lines, drug efflux transporters such as MDR1, MRP1, and BCRP were highly expressed in resistant cell lines. Drug efflux transporters have been identified not only in cell lines but also in EVs released from parental cells using immunoaffinity-based EV isolation. The expression of drug resistance markers in EVs was relatively high in patients with residual disease compared to those with a pathological complete response.

Conclusions

The optimal combination of drug-resistant EV markers was significantly efficient in predicting resistance to NAC with 81.82% sensitivity and 92.86% specificity.
Appendix
Available only for authorised users
Literature
1.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, et al. NCCN Guidelines® insights: breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594–608.CrossRefPubMed
2.
Zaheed M, Wilcken N, Willson ML, O’Connell DL, Goodwin A. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019;2:CD012873.PubMed
3.
Colomer R, Saura C, Sanchez-Rovira P, Pascual T, Rubio IT, Burgues O, Marcos L, Rodriguez CA, Martin M, Lluch A. Neoadjuvant Management of early breast Cancer: a clinical and investigational position Statement. Oncologist. 2019;24(5):603–11.CrossRefPubMedPubMedCentral
4.
Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, et al. Pathologic Complete Response after neoadjuvant chemotherapy and impact on breast Cancer recurrence and survival: a Comprehensive Meta-analysis. Clin Cancer Res. 2020;26(12):2838–48.CrossRefPubMedPubMedCentral
5.
An SJ, Duchesneau ED, Strassle PD, Reeder-Hayes K, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM. Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2 + breast cancer. NPJ Breast Cancer. 2022;8(1):65.CrossRefPubMedPubMedCentral
6.
Luque-Bolivar A, Perez-Mora E, Villegas VE, Rondon-Lagos M. Resistance and overcoming resistance in breast Cancer. Breast Cancer (Dove Med Press). 2020;12:211–29.PubMed
7.
Willms E, Cabanas C, Mager I, Wood MJA, Vader P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in Cancer Progression. Front Immunol. 2018;9:738.CrossRefPubMedPubMedCentral
8.
Li SR, Man QW, Gao X, Lin H, Wang J, Su FC, Wang HQ, Bu LL, Liu B, Chen G. Tissue-derived extracellular vesicles in cancers and non-cancer diseases: Present and future. J Extracell Vesicles. 2021;10(14):e12175.CrossRefPubMedPubMedCentral
9.
Xavier CPR, Belisario DC, Rebelo R, Assaraf YG, Giovannetti E, Kopecka J, Vasconcelos MH. The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells. Drug Resist Updat. 2022;62:100833.CrossRefPubMed
10.
Papp AC, Azad AK, Pietrzak M, Williams A, Handelman SK, Igo RP Jr., Stein CM, Hartmann K, Schlesinger LS, Sadee W. AmpliSeq transcriptome analysis of human alveolar and monocyte-derived macrophages over time in response to Mycobacterium tuberculosis infection. PLoS ONE. 2018;13(5):e0198221.CrossRefPubMedPubMedCentral
11.
Li W, Turner A, Aggarwal P, Matter A, Storvick E, Arnett DK, Broeckel U. Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genomics. 2015;16:1069.CrossRefPubMedPubMedCentral
12.
Wang L, Feng Z, Wang X, Wang X, Zhang X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 2010;26(1):136–8.CrossRefPubMed
13.
Kim MW, Park S, Lee H, Gwak H, Hyun KA, Kim JY, Jung HI, Kim SI. Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer. Cancer Sci. 2021;112(12):5078–87.CrossRefPubMedPubMedCentral
14.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.CrossRefPubMed
15.
Famta P, Shah S, Chatterjee E, Singh H, Dey B, Guru SK, Singh SB, Srivastava S. Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms. Curr Res Pharmacol Drug Discov. 2021;2:100054.CrossRefPubMedPubMedCentral
16.
17.
Giddings EL, Champagne DP, Wu MH, Laffin JM, Thornton TM, Valenca-Pereira F, Culp-Hill R, Fortner KA, Romero N, East J, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun. 2021;12(1):2804.ADSCrossRefPubMedPubMedCentral
18.
Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.CrossRefPubMedPubMedCentral
19.
Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Sci Rep. 2017;7:45477.ADSCrossRefPubMedPubMedCentral
20.
Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggs A, Karantza V, Aktan G, Qi CZ, et al. Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival outcomes in Triple-negative breast Cancer. J Natl Compr Canc Netw. 2020;18(8):1096–104.CrossRefPubMed
21.
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367(6478).
22.
Yu DD, Wu Y, Shen HY, Lv MM, Chen WX, Zhang XH, Zhong SL, Tang JH, Zhao JH. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 2015;106(8):959–64.CrossRefPubMedPubMedCentral
23.
Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, Zhang J, Chen L, Tang JH, Zhao JH. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014;35(11):10773–9.CrossRefPubMed
24.
Chen WX, Zhong SL, Ji MH, Pan M, Hu Q, Lv MM, Luo Z, Zhao JH, Tang JH. MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol. 2014;35(4):2883–92.CrossRefPubMed
25.
Kovalev AA, Tsvetaeva DA, Grudinskaja TV. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 2013;35(4):287–90.PubMed
26.
27.
28.
Yao T, Cao R, Xiao W, Pan F, Li X. An optical study of drug resistance detection in endometrial cancer cells by dynamic and quantitative phase imaging. J Biophotonics. 2019;12(7):e201800443.CrossRefPubMedPubMedCentral
29.
Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. Embo J. 2016;35(5):462–78.CrossRefPubMed
30.
Begicevic RR, Falasca M. ABC transporters in Cancer Stem cells: beyond Chemoresistance. Int J Mol Sci 2017;18(11).
31.
Kim B, Stephen SL, Hanby AM, Horgan K, Perry SL, Richardson J, Roundhill EA, Valleley EM, Verghese ET, Williams BJ, et al. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer. 2015;15:634.CrossRefPubMedPubMedCentral
32.
Kim B, Fatayer H, Hanby AM, Horgan K, Perry SL, Valleley EM, Verghese ET, Williams BJ, Thorne JL, Hughes TA. Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS ONE. 2013;8(5):e62766.ADSCrossRefPubMedPubMedCentral
33.
Keyvani-Ghamsari S, Khorsandi K, Rasul A, Zaman MK. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenetics. 2021;13(1):120.CrossRefPubMedPubMedCentral
34.
Wainwright EN, Scaffidi P. Epigenetics and Cancer Stem cells: unleashing, hijacking, and restricting Cellular plasticity. Trends Cancer. 2017;3(5):372–86.CrossRefPubMedPubMedCentral
35.
Modi A, Roy D, Sharma S, Vishnoi JR, Pareek P, Elhence P, Sharma P, Purohit P. ABC transporters in breast cancer: their roles in multidrug resistance and beyond. J Drug Target 2022:1–21.
36.
Zhang YS, Yang C, Han L, Liu L, Liu YJ. Expression of BCRP/ABCG2 protein in invasive breast Cancer and response to Neoadjuvant Chemotherapy. Oncol Res Treat. 2022;45(3):94–101.CrossRefPubMed
37.
He J, Fortunati E, Liu DX, Li Y. Pleiotropic roles of ABC transporters in breast Cancer. Int J Mol Sci 2021;22(6).
38.
Zhou E, Li Y, Wu F, Guo M, Xu J, Wang S, Tan Q, Ma P, Song S, Jin Y. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine. 2021;67:103365.CrossRefPubMedPubMedCentral
39.
Konig L, Kasimir-Bauer S, Bittner AK, Hoffmann O, Wagner B, Santos Manvailer LF, Kimmig R, Horn PA, Rebmann V. Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy. Oncoimmunology. 2017;7(1):e1376153.CrossRefPubMedPubMedCentral
40.
Tian F, Zhang S, Liu C, Han Z, Liu Y, Deng J, Li Y, Wu X, Cai L, Qin L, et al. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun. 2021;12(1):2536.ADSCrossRefPubMedPubMedCentral
Metadata
Title
Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy
Authors
Min Woo Kim
Hyojung Lee
Suji Lee
Sol Moon
Young Kim
Joon Ye Kim
Seung Il Kim
Jee Ye Kim
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11822-9

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Study Protocol

mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial

Research

Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan

Research

Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis

Research

Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery

Research

Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms

Research

FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits